Autolus Therapeutics plc (AUTL) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $1.60: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells... Read more
Sell if holding. Engine safety override at $1.60: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Volatile — 6.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $1.60: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $1.47. Score 5.2/10, moderate confidence.
Take-profit target: $1.71 (+8.2% upside). Prior stop was $1.47. Stop-loss: $1.47.
DATA_ISSUE: analyst_target_implausible (raw $8.55 vs price $1.58 — ratio 5.4×). Rejected, falling back to technical TP.; Quality below floor (1.7 < 4.0).
Autolus Therapeutics plc trades at a P/E of N/A (forward -2.6). TrendMatrix value score: 10.0/10. Verdict: Sell.
17 analysts cover AUTL with a consensus score of 4.3/5. Average price target: $9.
What does Autolus Therapeutics plc do?Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of...
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.